IRLAB Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mesdopetam (IRL790) / Ipsen
2020-002010-41: A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson’s disease

Not yet recruiting
2
140
Europe
mesdopetam, IRL790, Capsule
Integrative Research Laboratories Sweden AB (IRLAB), Integrative Research Laboratories Sweden AB, Integrative Research Laboratories Sweden AB (IRLAB)s, Integrative Research Laboratories AB (IRLAB)
Parkinson's disease dyskinesia, Parkinson's disease dyskinesia refers to a group of involuntary movement disorders. Dyskinesia can be anything from a slight tremor of the handds to an uncontrollable movement of the body., Diseases [C] - Nervous System Diseases [C10]
 
 
pirepemat (IRL752) / IRLAB Therap
2019-002627-16: A study for evaluation of the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease Badanie oceniające skuteczność pirepematu na częstość upadków upacjentów z chorobą Parkinsona

Ongoing
2
165
Europe
Pirepemat, 50 mg, Pirepemat, 100 mg, IRL752, Film-coated tablet
Integrative Research Laboratories Sweden AB (IRLAB), Integrative Research Laboratories Sweden AB (IRLAB)
Parkinson’s disease, Parkinson’s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05258071: A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients with Parkinson's Disease (PD)

Completed
2
104
Europe
Pirepemat, IRL752, Placebo
Integrative Research Laboratories AB
Parkinson Disease
12/24
01/25
IRL757 / IRLAB Therap
NCT06493045: First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Completed
1
82
Europe
IRL757, Placebo
Integrative Research Laboratories AB, Michael J. Fox Foundation for Parkinson's Research
Not Determined
02/25
02/25
NCT06699628: Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

Completed
1
12
Europe
IRL757
Integrative Research Laboratories AB
Not Applicable As This is a Mass Balance/pharmacokinetic Study Performed in Healthy Subjects, Apathy
11/24
11/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mesdopetam (IRL790) / Ipsen
2020-002010-41: A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson’s disease

Not yet recruiting
2
140
Europe
mesdopetam, IRL790, Capsule
Integrative Research Laboratories Sweden AB (IRLAB), Integrative Research Laboratories Sweden AB, Integrative Research Laboratories Sweden AB (IRLAB)s, Integrative Research Laboratories AB (IRLAB)
Parkinson's disease dyskinesia, Parkinson's disease dyskinesia refers to a group of involuntary movement disorders. Dyskinesia can be anything from a slight tremor of the handds to an uncontrollable movement of the body., Diseases [C] - Nervous System Diseases [C10]
 
 
pirepemat (IRL752) / IRLAB Therap
2019-002627-16: A study for evaluation of the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease Badanie oceniające skuteczność pirepematu na częstość upadków upacjentów z chorobą Parkinsona

Ongoing
2
165
Europe
Pirepemat, 50 mg, Pirepemat, 100 mg, IRL752, Film-coated tablet
Integrative Research Laboratories Sweden AB (IRLAB), Integrative Research Laboratories Sweden AB (IRLAB)
Parkinson’s disease, Parkinson’s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05258071: A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients with Parkinson's Disease (PD)

Completed
2
104
Europe
Pirepemat, IRL752, Placebo
Integrative Research Laboratories AB
Parkinson Disease
12/24
01/25
IRL757 / IRLAB Therap
NCT06493045: First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Completed
1
82
Europe
IRL757, Placebo
Integrative Research Laboratories AB, Michael J. Fox Foundation for Parkinson's Research
Not Determined
02/25
02/25
NCT06699628: Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

Completed
1
12
Europe
IRL757
Integrative Research Laboratories AB
Not Applicable As This is a Mass Balance/pharmacokinetic Study Performed in Healthy Subjects, Apathy
11/24
11/24

Download Options